May & Baker Nigeria Plc
Every TNI analysis that covers May & Baker Nigeria Plc.
Nigerian Pharma 9M 2026 Scorecard: May & Baker Wins on Quality, Fidson on Scale, MeCure Carries the Debt
A calmer naira and lower FX losses lifted every listed drugmaker in 2026. Only May & Baker turned that into clean, cash-backed, cheaply priced earnings.
9 November 2026 · Read analysis →May & Baker 9M 2026: A 10-Point Margin Leap, Net Cash and a Single-Digit P/E
May & Baker's PAT rose 76% to N5.89bn on a 10ppt gross-margin jump. It holds net cash and trades near 9.7x trailing earnings, the best value in listed pharma.
9 November 2026 · Read analysis →